Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s diseaseTammie L.S. Benzinger, John C. Morris, Tyler Blazey et al.|Proceedings of the National Academy of Sciences|2013Cited by 388
Partial volume correction in quantitative amyloid imagingYi Su, Tammie L.S. Benzinger, Tyler Blazey et al.|NeuroImage|2014Cited by 253
Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trialSusan Mills, Randall J. Bateman, J. Mallmann et al.|Revue Neurologique|2013Cited by 136
Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer DiseaseJewell B. Thomas, Beau M. Ances, Matthew R. Brier et al.|JAMA Neurology|2014Cited by 135
Amyloid‐Related Imaging Abnormalities in the <scp>DIAN‐TU</scp>‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph‐Mathurin, Richard J. Perrin, Brian A. Gordon et al.|Annals of Neurology|2022Cited by 42